Free Trial
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

PolyPid logo
$2.94 -0.03 (-0.84%)
Closing price 03:55 PM Eastern
Extended Trading
$2.94 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PolyPid Stock (NASDAQ:PYPD)

Key Stats

Today's Range
$2.89
$2.98
50-Day Range
$2.74
$3.30
52-Week Range
$2.37
$5.50
Volume
1,577 shs
Average Volume
13,294 shs
Market Capitalization
$29.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33
Consensus Rating
Buy

Company Overview

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Remove Ads

PolyPid Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

PYPD MarketRank™: 

PolyPid scored higher than 41% of companies evaluated by MarketBeat, and ranked 661st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PolyPid has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PolyPid has only been the subject of 3 research reports in the past 90 days.

  • Read more about PolyPid's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PolyPid is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PolyPid is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PolyPid has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about PolyPid's valuation and earnings.
  • Percentage of Shares Shorted

    0.16% of the float of PolyPid has been sold short.
  • Short Interest Ratio / Days to Cover

    PolyPid has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PolyPid has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PolyPid does not currently pay a dividend.

  • Dividend Growth

    PolyPid does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.16% of the float of PolyPid has been sold short.
  • Short Interest Ratio / Days to Cover

    PolyPid has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PolyPid has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PolyPid has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • MarketBeat Follows

    Only 1 people have added PolyPid to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PolyPid insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 26.47% of the stock of PolyPid is held by institutions.

  • Read more about PolyPid's insider trading history.
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

PYPD Stock News Headlines

PolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100
Craig-Hallum Remains a Buy on PolyPid (PYPD)
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Analyzing PolyPid (NASDAQ:PYPD) & Nyxoah (NASDAQ:NYXH)
See More Headlines

PYPD Stock Analysis - Frequently Asked Questions

PolyPid's stock was trading at $3.04 on January 1st, 2025. Since then, PYPD stock has decreased by 4.9% and is now trading at $2.8910.
View the best growth stocks for 2025 here
.

PolyPid Ltd. (NASDAQ:PYPD) posted its earnings results on Wednesday, February, 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.23.

PolyPid shares reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

PolyPid's top institutional investors include Rosalind Advisors Inc. (10.03%), Rosalind Advisors Inc. (9.99%), AIGH Capital Management LLC (8.12%) and DAFNA Capital Management LLC (2.86%).

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU).

Company Calendar

Last Earnings
2/12/2025
Today
3/19/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+292.0%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.75 per share
Price / Book
3.85

Miscellaneous

Free Float
7,674,000
Market Cap
$29.46 million
Optionable
No Data
Beta
1.27
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:PYPD) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners